Cullinan Therapeutics saw its stock tick higher in pre-open trading, up 2.1%, after the company said it received constructive feedback from the U.S. Food and Drug Administration during an End-of-Phase 1 meeting for CLN-049. CLN-049 is described by the company as a FLT3xCD3 bispecific T cell engager being developed for patients with relapsed or refractory acute myeloid leukemia (AML).
Based on discussions with regulators, Cullinan indicated it intends to launch a potentially registrational Phase 2 study of CLN-049 in the third quarter of 2026. The planned trial design will include a short dose-optimization segment followed by a single-arm expansion cohort at the recommended Phase 2 dose. The company framed this structure as streamlined and interpreted by investors as a credible, accelerated path toward regulatory approval.
The CLN-049 program already carries two regulatory designations intended to facilitate development: FDA Fast Track designation and Orphan Drug Designation for relapsed/refractory AML. Those designations allow for more frequent engagement with the FDA and can support expedited review, according to the company statement.
In addition to the single-agent registrational plan, Cullinan said it plans to initiate a separate Phase 1/2 combination study evaluating CLN-049 together with venetoclax and azacitidine in previously untreated AML patients. The company presented the combination trial as a way to broaden the potential addressable population for CLN-049.
Market context provided limited support for biotech names on the day of the announcement. The NASDAQ was trading lower while the S&P 500 and the Dow Jones were modestly positive. Cullinan's pre-market rise appeared to reflect the company-specific regulatory update rather than broader sector momentum. The company reported no significant competitor announcements that would explain a sympathy move among peers.
Following the update, Cullinan moved toward $17.80 in pre-market trade. That level leaves the stock well above its 52-week low of $5.68 but still beneath its 52-week high of $19.43.
Data and positioning
- Pre-open gain: 2.1%.
- Planned Phase 2 start: Q3 2026, with a short dose-optimization phase and a single-arm expansion cohort at the recommended Phase 2 dose.
- Regulatory designations: FDA Fast Track and Orphan Drug Designation for relapsed/refractory AML.
- Planned combination study: separate Phase 1/2 trial of CLN-049 with venetoclax and azacitidine in previously untreated AML patients.
Market quote context
The stock's pre-market move and position relative to its 52-week range suggest investor focus on the regulatory roadmap for CLN-049 rather than on broader biotech sector strength.